Stay updated on AXS-05 in Treatment-Resistant Major Depressive Disorder Clinical Trial
Sign up to get notified when there's something new on the AXS-05 in Treatment-Resistant Major Depressive Disorder Clinical Trial page.

Latest updates to the AXS-05 in Treatment-Resistant Major Depressive Disorder Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe record now presents details of the completed Phase 3 STRIDE-1 study of AXS-05 versus bupropion for treatment-resistant major depressive disorder, including its eligibility criteria, study locations, and measured outcomes.SummaryDifference62%

- Check17 days agoChange DetectedThe footer’s site revision label changed from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA sitewide NIH banner announces updates and FAQs about the transition from “Artificial Intelligence” to “Super Intelligence.” It appears above the ClinicalTrials.gov 403 error page.SummaryDifference1%

- Check31 days agoChange DetectedThe page displays the ClinicalTrials.gov record for the completed STRIDE-1 study of AXS-05 for treatment-resistant major depressive disorder, including its design, eligibility criteria, and outcomes.SummaryDifference63%

- Check38 days agoChange DetectedThe footer revision number changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check52 days agoChange DetectedThe 403 error state is removed, and the page now presents the actual study details for NCT02741791. This reflects the page transitioning from an error to a usable study record.SummaryDifference0.5%

Stay in the know with updates to AXS-05 in Treatment-Resistant Major Depressive Disorder Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AXS-05 in Treatment-Resistant Major Depressive Disorder Clinical Trial page.